Cidara Therapeutics (NASDAQ:CDTX) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.11, Fidelity Earnings reports.
CDTX stock opened at $4.04 on Friday. The stock has a market capitalization of $115.69 million, a P/E ratio of -1.27 and a beta of 1.84. Cidara Therapeutics has a fifty-two week low of $3.36 and a fifty-two week high of $8.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.11 and a quick ratio of 7.11.
Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald set a $15.00 price objective on shares of Cidara Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 4th. Zacks Investment Research downgraded shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Needham & Company LLC set a $14.00 price objective on shares of Cidara Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 9th. Citigroup assumed coverage on shares of Cidara Therapeutics in a report on Wednesday, July 25th. They issued a “buy” rating and a $8.00 price objective for the company. Finally, ValuEngine raised shares of Cidara Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 17th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $10.50.
TRADEMARK VIOLATION WARNING: This report was first published by Macon Daily and is owned by of Macon Daily. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://macondaily.com/2018/11/10/cidara-therapeutics-cdtx-releases-quarterly-earnings-results-beats-estimates-by-0-11-eps.html.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.
Recommended Story: Asset Allocation
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.